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Purpose: To compare microsatellite instability (MSI)
testing with immunohistochemical (IHC) detection of
hMLH1 and hMSH2 in colorectal cancer.
Patients and Methods: Colorectal cancers from
1,144 patients were assessed for DNA mismatch repair
deficiency by two methods: MSI testing and IHC detec-
tion of hMLH1 and hMSH2 gene products. High-fre-
quency MSI (MSI-H) was defined as more than 30%
instability of at least five markers; low-level MSI (MSI-L)
was defined as 1% to 29% of loci unstable.
Results: Of 1,144 tumors tested, 818 showed intact
expression of hMLH1 and hMSH2. Of these, 680 were
microsatellite stable (MSS), 27 were MSI-H, and 111
were MSI-L. In all, 228 tumors showed absence of
hMLH1 expression and 98 showed absence of hMSH2
expression: all were MSI-H.
Conclusion: IHC in colorectal tumors for protein
products hMLH1 and hMSH2 provides a rapid, cost-
effective, sensitive (92.3%), and extremely specific
(100%) method for screening for DNA mismatch repair
defects. The predictive value of normal IHC for an MSS/
MSI-L phenotype was 96.7%, and the predictive value
of abnormal IHC was 100% for an MSI-H phenotype.
Testing strategies must take into account acceptability
of missing some cases of MSI-H tumors if only IHC is
performed.
J Clin Oncol 20:1043-1048. © 2002 by American
Society of Clinical Oncology.
IN THE NEAR FUTURE, there are likely to be importantclinical indications for determining the molecular type
of colorectal cancers (CRC). One parameter by which
colorectal cancers can be classified involves alterations in
the DNA mismatch repair process. Specifically, about 85%
of CRC possess normal DNA mismatch repair function,
whereas 15% have defective DNA mismatch repair. The
latter category includes mostly sporadic tumors in which
hMLH1 promotor methylation has rendered the DNA mis-
match repair complex incompetent. It also includes the
cancers associated with hereditary nonpolyposis colon can-
cer syndrome (HNPCC)/Lynch syndrome that carry a germ-
line mutation in one of the DNA mismatch repair genes,
usually hMLH1 or MSH2.
The tumor phenotype associated with either hereditary or
acquired loss of DNA mismatch repair competency is called
microsatellite instability (MSI). MSI phenotypes have been
subdivided into those with high (MSI-H) and low (MSI-L)
levels of instability, with MSI-H usually defined as insta-
bility at  30 of loci studied, and MSI-L defined as
instability at 1% to 29% of loci.1 All other tumors are
referred to as microsatellite stable (MSS). Uncertainty exists
about the clinical and biologic significance of the MSI-L
phenotype because, in most regards, the behavior of MSI-L
tumors is similar to that of MSS tumors.
There is a growing body of evidence that there are
clinical and histopathologic differences between MSI-H and
MSS/MSI-L colorectal cancers. Tumors with an MSI-H
phenotype are more likely to have mutations in genes with
short repetitive tracts such as the transforming growth factor
beta receptor gene, BAX genes, IGF2R gene, and others.2-7
MSI-H tumors are less likely to have loss of APC,8-17 or
mutations in p538,10,14-22 or K-ras8-10,14-16,19,20,23-25 com-
pared with MSS tumors. MSI-H tumors are more likely to
be diploid or nearly diploid,8,26-31 Carcinoembryonic anti-
gen expression is less common in MSI-H tumors.31 MSI-H
tumors more often arise in the right colon26,27,28,32 and are
more likely to occur in individuals with a positive family
history of colorectal cancer.26,27 A female predilection for
MSI-H tumors has been noted,7,30,33 and MSI-H tumors
may have a better stage-specific prognosis.26,27
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Additional differences are noted in the histopathologic
examination. MSI-H tumors are more likely to show crib-
riform/solid growth pattern and signet ring histology or
high-grade medullary histology28,30,31,34 and to be muci-
nous30,35,36 and exophytic.31 MSI-H tumors may show
enhanced immunologic response as determined by marked
lymphocytic infiltration of the tumor.30,36
Experiments have recently shown in vitro differences in
the response of MSI-H cell lines to chemotherapeutic
agents. DNA mismatch repair-deficient cells are resistant to
the alkylating agents melphalan and busulphan; the methy-
lating agents procarbazine and temozolomide; the platinum-
containing agents cisplatin and carboplatin; the antimetabo-
lites 6-thioguanine, fluorouracil, and O6-methylguanine;
and the topoisomerase inhibitors etoposide and doxorubicin
(reviewed in37-39). The clinical significance of these obser-
vations remains unclear; however, one recent publication40
described striking survival benefits in patients with right-
sided colonic tumors who received adjuvant chemotherapy
compared with those who did not. Little benefit from
adjuvant therapy was noted in patients with left-sided
tumors. Right-sided colon tumors are much more frequently
MSI. The authors therefore suggest additional prospective
studies on the predictive value of MSI regarding benefits
from adjuvant chemotherapy. It does seem reasonable to
suspect the potential for different susceptibilities to chemo-
therapeutic agents in MSS versus MSI-H tumors in light of
the differences catalogued above.
Presently, determination of DNA mismatch repair com-
petency status from CRC is offered in situations in which
the diagnosis of HNPCC/Lynch syndrome is being consid-
ered; for example, in a proband with a positive family
history of CRC or a very young individual with a diagnosis
of CRC. As more is learned about differential responses to
therapies between tumors with and without DNA mismatch
repair competency, one must anticipate that testing will
become even more widely conducted, perhaps encompass-
ing all cases of newly diagnosed CRC in order to tailor
therapeutic regimens to the biology of the colorectal tumor.
The current “gold standard” for assessing tumor DNA
mismatch pair competency is molecular MSI testing. This is a
labor-intensive test that involves extracting DNA from both
tumor and normal tissue excised at surgery. The DNA is
subjected to polymerase chain reaction (PCR) amplification of
five or more different chromosomal loci that compare “micro-
satellites” (simple sequence repeat such as a CA dinucleotide
repeat), running the PCR products through a gel to separate
DNA fragments by size, comparing the tumor-normal pairs,
and scoring for differences (MSI) between the two. Generally,
instability at two or more out of five markers (or  30% of
markers tested) defines a tumor as MSI-H.
The intensive and time-consuming nature of this test is
particularly clinically troublesome, because surgeons would
frequently like to know preoperatively if a patient is likely
to have HNPCC. This information might change the extent
of the colectomy that is performed and lead to consideration
for simultaneous hysterectomy and oophorectomy as well.
The time frame from diagnosis to surgery is generally
insufficient to allow tumor MSI results to be available at the
time surgical decisions are being made.
It is known that in HNPCC, mutations in two of the DNA
mismatch repair genes, known as hMLH1 and hMSH2,
account for about two thirds of families meeting Amsterdam
criteria. However, in HNPCC patients with tumors with the
MSI-H phenotype, nearly all families are thought to carry
germline mutations in hMLH1 or hMSH2 (mutations in
hMSH6, hMSH3, hPMS2 are extremely uncommon). Fur-
thermore, in sporadic tumors with MSI-H phenotype, a very
high proportion of all tumors have methylation of the
hMLH1 promotor. Therefore, hMLH1 or hMSH2 are either
mutated or methylated in the vast majority of MSI-H tumors
identified to date. Monoclonal antibodies to the protein
products of both hMLH1 and hMSH2 are now commercially
available. This technique is far less labor intensive than
traditional MSI testing, and the results can be available to
inform clinical decisions within 24 hours.
We sought to determine the correlation between tumor
MSI status and tumor IHC for the protein products of
hMLH1 and hMSH2, reasoning that if IHC was sufficiently
sensitive and specific, tumor IHC might provide a rapid and
cost-effective method for categorizing colorectal cancers
into mismatch repair competency subgroups.
PATIENTS AND METHODS
Patient/Tumor Ascertainment
Tumors for this study came from a number of different sources. Three
centers from the Cooperative Family Registry for Colon Cancer Studies
(CFRs) participated in this study (additional information about the CFRs
resource can be found at http://www-dccps.ims.nci.nih.gov/cfrccs/
q&a.html). Patients from the Mayo CFR site were recruited from three
sources: (1) Mayo Clinic Rochester patients; (2) North Central Cancer
Treatment Group patients, a consortium of community-based oncology
practices throughout the middle United States; and (3) via the Minnesota
Cancer Surveillance System, a population-based state cancer registry.
Patients from the Australia CFR site were recruited from multiple family
cancer clinics throughout Australia. Patients from the Ontario CFR site
were recruited from a population-based cancer registry from throughout
Ontario. All CFR sites had appropriate institutional review board review of
protocols, and participants gave written informed consent for collection of
blood and tumor tissue for use in cancer research. Patients completed
extensive epidemiology questionnaires, family history was obtained, and
additional affected and unaffected relatives were also invited to participate
in the CFRs. The tumors from a variety of hospitals throughout the United
States, Australia, and Canada were preserved in a variety of ways, and
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tumor blocks varied in age from less than 1 year to more than 15 years
since resection. The numbers and ages of patients in this study are listed in
Table 1.
In addition, we pooled CFRs data with a series of unselected,
consecutive cases of colorectal cancers resected at Mayo Clinic
Rochester. These cases (hereafter called the Cancer Risk Assessment
[CRA] cases) were obtained from 257 of 514 patients who underwent
surgical resection during a 1.5-year period from December 1995 to
April 1997 (57.2% of those approached did agree to participate)
(Thibodeau et al, manuscript submitted for publication). There is no
overlap with the CFRs cases. The male/female ratio was 1.47 (153
men, 104 women). For the nonparticipants (n  199), the male/
female ratio was 1.1, indicating that male subjects were more likely
to participate than female subjects. The nonparticipants were also
older than the participants (median age, 72 v 69 years; P  .005).
Note that this aggregate data set is collected via oversampling of
high-risk colon cancer probands, and thus is not suitable for
determining such things as the frequency of MSI phenotypes in the
general colon cancer population.
DNA Extraction
DNA was extracted from frozen or paraffin-embedded tissues as
described previously.33 Briefly, DNA from microdissected frozen
tissue sections (10 m) was extracted by a standard phenol/chloroform
procedure. For tumor DNA, only those areas containing more than 70%
tumor cells were used. For DNA extraction from paraffin-embedded
tissues, the Qiamp tissue kit (Qiagen, Inc, Santa Clarita, CA) was used
according to the manufacturer’s instructions. The corresponding nor-
mal control DNA for each patient was derived from peripheral blood.
For these specimens, DNA was extracted using the Puregene nucleic
acid isolation kit (Gentra Systems, Minneapolis, MN).
MSI
For the CFRs tumors, paired normal and tumor DNA was
analyzed for MSI with 10 markers: mononucleotide markers
BAT25, BAT26, BAT40, BAT34C4; dinucleotide markers D5S346,
D17S250, ACTC, D18S55, and D10S197; and penta-mono-tetra
compound marker MYCL.
For the CRA group, paired normal and tumor DNA were analyzed
for MSI with six dinucleotide microsatellite markers (D5S346, TP53,
D18S34, D18S49, D18S61, and ACTC) and one mononucleotide
repeat (BAT 26). PCR and gel electrophoresis were carried out as
described by Thibodeau et al.26 Tumors were classified as MSI-H if 
30% markers demonstrated instability, MSI-L if  30% demonstrated
MSI, and MSS if no marker exhibited MSI.1,33
Immunohistochemical Analysis
For immunohistochemical (IHC) analysis performed at the Mayo
Clinic, tissue sections were cut at 6 m and mounted on Probe On
charged slides (Fisher Scientific, Pittsburgh, PA). After deparaffiniza-
tion, slides were steam pretreated in EDTA buffer, pH 8.0, in a Black
& Decker Handy Steamer Plus (Black & Decker, Shelton, CT) for 30
minutes. After rinsing in cool water, slides were loaded onto the Tech
Mate 500 (Ventana Medical Systems, Tuscon, AZ) automated immu-
nohistochemical stainer. The stainer uses capillary gap technology as
the primary mode of operation. In order for successful staining
performance, a gap measuring between 75 and 200 m must be formed
between two slides where the tissues are face to face.
Staining is performed using an avidin-biotin complex methodol-
ogy, supplied in kit form from Ventana Medical Systems (Biotek
Solutions buffer kit, Biotek Solutions DAB detection kit). This test
uses a primary antibody against hMLH1 (clone G168-728, 1/250;
Pharmingen, San Diego, CA) and hMSH2 (clone FE11, 1/50;
Oncogene Research Products, Cambridge, MA) that has been titered
on colon cancer sections and also tested on various normal and
pathologic tissue specimens.
IHC in Australia used 4-m sections that were affixed to Superfrost
Plus adhesive slides (Fisher Chemical Co, Pittsburgh, PA) and air-dried
overnight at 37°C. Antigen retrieval was performed in 0.001 mol/L EDTA,
pH 8.0, in an autoclave on “wet” cycle for 30 minutes. The sections were
cooled in EDTA buffer for 20 minutes before being transferred to
tris-buffered saline (TBS) (pH 7.4). Endogenous peroxidase activity was
blocked by immersing the slides in 1.0% H2O2, 0.1% NaN3 in TBS for 10
minutes. Nonspecific antibody binding was inhibited by incubating the
sections in 4% commercial nonfat skim milk powder in TBS for 15
minutes; then, after a brief rinse in TBS, the slides were transferred
to a humidified chamber and incubated with 10% nonimmune
normal goat serum. Excess nonimmune serum was decanted from
the slides and sections were incubated with primary antibody
overnight at room temperature. The primary antibodies used were
MLH1, clone G168-15 (BD PharMingen, Franklin Lakes, NJ) 1/75;
and MSH2, clone G219-1129 (PharMingen), 1/150.
The sections were washed in TBS and then transferred to a Shandon
Sequenza staining system (Thermo-Trace, Noble Park, VIC, Australia).
To block endogenous biotin-like activity unmasked by the antigen
retrieval step, the slides were subjected to biotin blocking using the
Dako Biotin Blocking kit (Dako, Carpinteria, CA) according to the
manufacturer’s instructions. The sections were incubated with biotin-
ylated goat antimouse immunoglobulins (Jackson ImmunoResearch,
West Grove, PA), diluted 1/250 in TBS for 45 minutes, then with
streptavidin–horseradish peroxidase conjugate (Jackson ImmunoRe-
search) diluted 1/500 in TBS for 15 minutes. Antigenic sites were
identified using 0.05% 3,3'-diaminobenzidine with H2O2 as substrate, and
were then lightly counterstained with Mayer’s hematoxylin before being
permanently mounted using DePeX (BDH-Gurr, Poole, United Kingdom).
Statistical Methods
Sensitivity and specificity for IHC classification for MSI-H status
was defined using the MSI results as the gold standard. Exact 95%
confidence intervals (CIs) were calculated using the binomial distribu-
tion. Sensitivity was defined as the absence of hMLH1 and hMSH2
expression by IHC in MSI-H tumors. Specificity was defined as intact
expression of hMLH1 and hMSH2 by IHC in MSS or MSI-L tumors.
RESULTS
Of the 1,144 cases examined, 350 (30.6%) were classified
as MSI-H by MSI testing. Of these, 323 showed absence of
either hMLH1 (70.6%) or hMSH2 (29.4%) expression by
Table 1. Summary of Patients Included in This Analysis
Ascertainment Site No. of Cases
Age (years)
Mean Range
Mayo CFR 337 54 28-77
Mayo CRA consecutive case series 255 69 29-91
Australia CFR 284 50 17-80
Australia consecutive case series 136 67 18-96
Ontario CFR 132 NA
Total 1,144
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IHC, for a sensitivity of 92.3% (95% CI, 88.9% to 94.9%).
Of the 794 cases found to be MSS or MSI-L by MSI testing,
794 (100%) showed normal IHC expression of both pro-
teins, for a specificity of 100% (95% CI, 99.5% to 100%).
The observed predictive value of absence of expression of
either hMLH1 or hMSH2 (no cases showed absence of both)
for predicting MSI-H status was 100%. The predictive value
of normal expression of both of these proteins for predicting
MSS/MSI-L status was 96.7%. Results of testing of 1,144
colorectal cancers for MSI testing and IHC for hMLH1/
hMSH2 are listed in Table 2.
DISCUSSION
This comparative study provided an opportunity to assess
the strengths and weaknesses of tumor MSI testing versus
tumor IHC for determining the competence of the mismatch
repair mechanism of tumors. Our interest was to determine
the correlation between IHC and MSI, not in how to best
diagnose HNPCC, nor were we trying to determine fre-
quency of MSI in CRCs. Overall, this study showed that
absence of expression of hMLH1 or hMSH2 had a 100%
specificity for predicting a tumor with MSI-H phenotype
(302 of 302). On the other hand, an MSI-H phenotype was
present in 3.3% of tumors with normal expression of both
hMLH1 and hMSH2 (27 of 818 tumors). The sensitivity of
IHC for detecting MSI-H tumors was 92.3%. That is, 326 of
353 tumors with MSI-H phenotype had absence of expres-
sion of either hMLH1 or hMSH2. Thus, in this mixed patient
population that is oversampled for high-risk factors (young
age, positive family history), an abnormal IHC test has a
100% predictive value for an MSI-H tumor phenotype, and
a normal IHC test for these two proteins has a 96.7%
predictive value for an MSS/MSI-L phenotype.
Others have looked at the issue of IHC versus MSI in
smaller series in different populations for different reasons.
Two groups have found 100% correspondence between tumor
MSI results and tumor IHC. Dieumegard et al41 reported that
15 MSI-H tumors they studied had lack of expression of either
hMSH2 or hMLH1 in each case, whereas normal expression
was found in 17 MSS tumors. Cawkwell et al42 studied 502
colorectal cancers. Sixty-six showed an MSI-H phenotype and
all (100%) were associated with complete lack of expression of
either hMSH2 or hMLH1.
On the other hand, other groups have found less than 100%
correspondence between these technologies. Debniak et al43
studied 168 patients with CRC including 25 with suspected or
known HNPCC. In this study, IHC was normal in 9% of cases
(four of 43) in which an MSI-H tumor phenotype was found.
Marcus et al44 studied the expression of hMLH1 and hMSH2 in
72 formalin-fixed, paraffin-embedded tumors. MSI-H pheno-
type was predicted correctly in 37 of 38 tumors (97%). IHC
expression was normal in all tumors without instability (34 of
34). Terdiman et al45 used IHC on 38 MSI-H tumors, and four
tumors (10.5%) had normal IHC (five were equivocal). Chaves
et al46 studied 76 cases of sporadic CRC and found MSI-H
phenotype in nine cases; IHC detected only 75% of these.
Ward et al47 studied 308 colon tumors and found that 27 of 33
(82%) of MSI-H tumors had loss of hMLH1 or hMSH2.
Tumor hMLH1/hMSH2 IHC has many clear advantages
over tumor MSI testing. If test costs are set according to actual
workload, IHC will be much less expensive than MSI testing,
and IHC can be performed more rapidly. Debniak et al43
estimate that IHC costs only 14% to 28% of what MSI testing
costs. On the basis of our experience, using workload record-
ings, we would agree with this estimate. Another substantial
advantage of tumor IHC over MSI testing is that IHC outcome
will guide clinicians to the correct gene for genetic testing in
individuals/families in which the issue of HNPCC is under
investigation. That is, absence of expression of either hMLH1
or hMSH2 indicates which gene is likely involved in an
HNPCC family. Additionally, tumor IHC can be conducted on
tiny tumor fragments such as those typically obtained from a
Table 2. Comparison of Colorectal Cancer IHC Results With MSI Results by Center
No. of Tumors With Intact Expression of MLH1 and
MSH2 by IHC
No. of Tumors With Absent Expression of MLH1
by IHC
No. of Tumors With Absent Expression of
MSH2 by IHC
A B C D  A B C D  A B C D 
Total no. of cases
(N  1,144)
274 204 251 89 818 41 48 116 23 228 22 3 53 20 98
No. of MSS 215 186 199 80 0 0 0 0 0 0 3* 0
No. of MSI-H 12 0 8 7 41 48 116 23 22 3 50 20
No. of MSI-L 47 18 44 2 0 0 0 0 0 0 0 0
NOTE. Patient populations were not comparable across centers. The cases in B were not selected for high-risk findings and the cases in C had the highest risk
profiles for hereditary cancers. This study does address incidence of MSI-H phenotype and should not be used for this purpose.
Abbreviations: A, Mayo CFR cases; B, Mayo CRA cases; C, Australian cases; D, Ontario cases; , total for each category; MSS, all tested microsatellites were
stable; MSI-H,  30% or more of microsatellites tested were unstable; MSI-L, 1-29% of tested microsatellites were unstable.
*These three cases would not have been reported clinically as MSS because there was insufficient tumor burden in the postirradiated specimens to perform MSI testing
reliably, and are included here only to highlight this technical issue in MSI testing. Germline mutations in hMSH2 were present in the families of these three cases.
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needle or colonoscopic biopsy. This type of fragment would
frequently yield insufficient DNA to conduct MSI testing.
Are there differences in the likelihood of achieving a
technically satisfactory test result between IHC or MSI
testing? We did not systematically collect all the data
required to answer this question, but made some observa-
tions as the data were collected. First, there may be a higher
success rate for all testing using fresh tissue compared with
archived tissues. With the CRA study, which used fresh
frozen tissues, there were no technical failures for either
MSI or IHC. With the Mayo CFR archival collection, we
observed seven tumors in which MSI testing was techni-
cally unsuccessful (amplified in only one or two of the 10
attempted markers), but tumor IHC was successful in six of
these cases. This included two cases with absence of
hMLH1 expression and two cases with absence of hMSH2
expression. Alternatively, there were also two cases in
which IHC failed but MSI was successful. Additional
prospective studies are needed to look systematically at
success rates between these two tests.
If the MSI status was determined solely on the basis of the
IHC surrogate, what would IHC of hMHL1/hMSH2 be ex-
pected to miss? Tumor MSI is a reflection of DNA mismatch
repair function. Two hits to any of the other components of the
DNA mismatch repair system (eg, hMSH6, hPMS2) can cause
MSI-H tumor phenotype that would not be predicted by
looking only at hMLH1/hMSH2 IHC. In addition, it is possible
that missense mutations in hMLH1/hMSH2 may exist that
transcribe and translate a stable but nonfunctional immunore-
active protein. This would give an apparently normal IHC.
Among the discordant cases at Mayo and in Australia, prelim-
inary work indicates that at least some of these cases are
because of inactivation of hMSH6 and hPMS2, although some
cases remain unexplained.
Note also that in the three Australian cases with absent
expression of hMSH2 but no MSI, all three were rectal cancer
cases that had been irradiated before resection. The very few
tumor cells that were present in the specimen (estimated as 
3%) were not enough to yield an MSI-H phenotype, but were
sufficient to be detected as islands of hMSH2 deficient tumor
cells by IHC. This MSI result would not have been reported
clinically because it was apparent that the specimen was not
suitable for reliable MSI testing. For the CFRs, sections with
more than 70% tumor are generally used. It is clear that
discrepant IHC/MSI results should prompt a search for a
biologic/clinical/technical explanation for this finding and not
just assume one test is “wrong.”
What threshold for test sensitivity is acceptable for catego-
rizing colorectal tumors as DNA mismatch repair proficient or
not? The answer to that question surely depends on why the
test is being ordered. If the goal is to identify HNPCC kindreds
for making a rapid surgical decision or in offering genetic
mutation analysis, that is different from categorizing for
purposes of tailoring potential chemotherapy. IHC appears to
offer a faster and less expensive alternative to MSI testing for
classifying colorectal cancers by mismatch repair competency
with essentially 100% specificity and greater than 92% sensi-
tivity. Clinicians must decide on a case-by-case basis if they
are comfortable with the predictive value of the IHC testing for
a particular patient. This weighting may shift if the utility of
colorectal tumor phenotyping becomes more important in
informing treatment decisions.
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